Curtis Chow, NP
Occupational Health · Redding, CANPI 1750461794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $887 and has fallen 50.1% since, to $443 in 2025. Among occupational health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $38.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$603
- Novo Nordisk$342
- Esperion Therapeutics, Inc.$193
- Lilly USA, LLC$180
- Medtronic$168
- GSK$162
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $603 |
| Novo Nordisk | 3 | $342 |
| Esperion Therapeutics, Inc. | 3 | $193 |
| Lilly USA, LLC | 7 | $180 |
| Medtronic | 2 | $168 |
| GSK | 8 | $162 |
| AbbVie | 7 | $142 |
| Eisai Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $114 |
| Sanofi | 1 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $110 |
| Exact Sciences | 6 | $108 |
| Pfizer | 3 | $80 |
| Alnylam Pharmaceuticals Inc. | 1 | $76 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Tandem Diabetes Care, Inc. | 1 | $73 |
| Amgen | 3 | $70 |
| Corcept Therapeutics | 1 | $67 |
| Coloplast | 1 | $41 |
| Abbott | 2 | $37 |
| Organon | 1 | $29 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Merck | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,988 in reported general payments places this provider in the 95th percentile of 33 occupational health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $108,026 |
| MounjaroTirzepatide | 44 | $84,683 |
| EliquisApixaban | 51 | $79,080 |
| RybelsusSemaglutide | 28 | $72,480 |
| FarxigaDapagliflozin Propanediol | 44 | $72,110 |
| TrulicityDulaglutide | 36 | $55,937 |
| JardianceEmpagliflozin | 40 | $54,776 |
| XareltoRivaroxaban | 26 | $38,113 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 94 | $20,980 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 61 | $19,477 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $12,083 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,698 |
| MyrbetriqMirabegron | 11 | $11,511 |
| Rosuvastatin Calcium | 495 | $9,672 |
| EntrestoSacubitril/Valsartan | 11 | $8,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $342 | $180,50682 claims |
| Lilly USA, LLCMounjaro, Trulicity | $180 | $140,62080 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $603 | $83,80857 claims |
| PfizerEliquis | $80 | $79,08051 claims |
| Boehringer IngelheimJardiance | $15 | $54,77640 claims |
| GSKShingrix, Arexvy | $162 | $40,457155 claims |
| AbbVieSynthroid | $142 | $3,60643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 occupational health providers in California.
Other occupational health in Redding
- John KellyVisalia$18K
- Cynthia McNaughtonMountain View$2K
- Teresa SimasVisalia$2K
- Danny SongSan Diego$1K
- Barbara RegisSan Diego$1K
- Leilani WagnerModesto$1K
- Marlene MuirSan Ramon$781
- Ekaterina CarmenattyStanford$397
- Nancy SeilerSan Luis Obispo$268
- Evangelina RamirezLos Angeles$223
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.